Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript [Seeking Alpha]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Seeking Alpha
Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Anthony Casciano - Chief Commercial Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Michael Yee - UBS Investment Bank, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Gregory Renza - Truist Securities, Inc., Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Jacob Goell - Wells Fargo Securities, LLC, Research Division J
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $37.00 to $31.00. They now have an "outperform" rating on the stock.MarketBeat
- A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi-Month Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- VRDN's page on the SEC website